Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Pancreatic cancer is the third leading cause of cancer related death, and is predicted to be the second within a decade. The overall five-year survival is less than 5%, one of the lowest among all cancer types, and this survival rate has not changed for more than 50 years. Recent large scale genomic studies demonstrated vast inter-tumoural heterogeneity, which may have contributed to the challenges in therapeutic development. In this talk, the key results of recent genomic studies will be presented, and novel therapeutic strategies using a personalised approach will be discussed.

References: Biankin et al, Nature 2012; Waddell et al, Nature 2015; Biankin et al, Nature 2015; Bailey et al, Nature 2016


David ChangDr David Chang is Senior Clinical Lecturer at the Wolfson Wohl Cancer Research Centre, University of Glasgow and Consultant Pancreatic Surgeon at Glagow Royal Infirmary.